Rapid Review Response HIV Medication and Depression

Similar documents
THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

HIV Drugs and the HIV Lifecycle

HIV medications HIV medication and schedule plan

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920

HIV Management Update 2015

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION

Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications

WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM

HIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Antiretroviral Dosing in Renal Impairment


HIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time

Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care

Nothing to disclose.

HIV Treatment Guidelines

October 26-28: Training Day 1

The Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018

OB/GYN CHART REVIEW DRAFT: NOT FOR DISTRTIBUTION

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV

HIV and YOU. Special 2008 Update!

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

ANTIRETROVIRAL TREATMENTS (Part 1of

continuing education for pharmacists

ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS

BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search

Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters

HIV Infection & AIDS in Low- and Middle-Income Countries

REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO

Midwestern Underwriting Conference 2016

Medscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection

Drug Treatment Program Update

Gilead Sciences, LLC 50

Bristol-Myers Squibb and Gilead Sciences, LLC 50

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 November 2010

PROGRESSIVE MULTI-FOCAL LEUKOENCEPHALOPATHY

Industry Data Request

Nobel /03/28. HIV virus and infected CD4+ T cells

NON-OCCUPATIONAL POST EXPOSURE PREVENTION. when you think you were exposed to hiv within the past three days

Sculpting a Better Regimen: The ART of HIV Medications

Antiretrovial Crushable/Liquid Formulation Chart

Simplifying HIV Treatment Now and in the Future

Antiretroviral Pregnancy Registry

A Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS

Industry Request Integrase Inhibitors

See Important Reminder at the end of this policy for important regulatory and legal information.

HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse

(609) (650) (609) (650)

ADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute

The ART of Antiretroviral Therapy in Critically-ill Patients with HIV

HIV epidemiology since HIV in the United States. HIV Transmission

HIV associated CNS disease in the era of HAART

Appropriate Use & Safety Edits

HIV and AIDS An update

Principles of Antiretroviral Therapy

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

Matters of the HAART: An Update on Current Treatment Options for HIV

FLORIDA!A MEDICAID' Better Health Care for all Floridians. May

JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet

PrE-Exposure Prophylaxis (PrEP) A Tool at Your Hand to Fight HIV

Human Immunodeficiency Virus Infection A Modern Day Epidemic

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids

Continuing Education for Pharmacy Technicians

P.I. Perspective. December 2008, Issue #47. Information, Inspiration and Advocacy for People Living with HIV/AIDS

Medication Errors Focus on the HIV-Infected Patient

When to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc

Distribution and Effectiveness of Antiretrovirals in the Central Nervous System

Central Nervous System Penetration of ARVs: Does it Matter?

Genotyping and Drug Resistance in Clinical Practice. Case Studies

HIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship

HIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine

PATIENT INFORMATION EMTRIVA

HIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop

FORMULARY Virginia (VA) AIDS Drug Assistance Program (ADAP) LAST UPDATED: December At a Glance: VA ADAP Formulary

Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and

ANTIRETROVIRAL THERAPY

See Important Reminder at the end of this policy for important regulatory and legal information.

Overview of HIV. LTC Paige Waterman

Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course

PHCP 403 by L. K. Sarki

An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist

Important Safety Information About TRUVADA to Reduce the Risk of Getting Human Immunodeficiency Virus 1 (HIV-1) Infection

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare

TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION

Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.

ART and Prevention: What do we know?

treatment passport 1

Addressing Pediatric Needs of the Most Neglected: next steps

Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update

Adherence Strategies for Older Adults. AIDS Community Research Initiative of America (ACRIA)

Risk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION. Jason E. Vercher, PA-C, AAHIVM

Transcription:

Rapid Review Response HIV Medication and Depression Question: Is depression a side effect of anti-retroviral medications taken by people living with HIV? The issue and why it s important The Ontario HIV and Substance Use Training Program offers workshops across Ontario for counselors working in the field. In the past these workshops have advised counselors to consider that someone with HIV may be experiencing depression as a side effect of their HIV medications, not just the HIV diagnosis. In order to ensure the accuracy of the information provided, the program requested a review of the research literature to determine whether HIV anti-retroviral medications result in depression for people living with HIV or AIDS. What we found Numerous studies have revealed that up to 50% of people living with HIV or AIDS experience depression (1-4). The available data suggests that depression leads to worse outcomes in people living with HIV. However, it is unclear whether this difference in outcomes is driven by depression or another factor such as differences in medication adherence or both. More research is needed to help further explain the relationship between depression, HAART and differences in medication adherence (5). There are many reasons why some people living with HIV experience depression. Biological and psychological mechanisms can explain this phenomenon (4). For example: Depression may be related to the psychological impact of an HIV positive test report and with the progression of HIV (6). Depression may be caused by HIV penetration of the blood-brain barrier and infection of the central nervous system (sometimes called organic depression ) (7). Depression may be caused by HIV-related opportunistic illness such as infections or tumors of the brain (also called organic depression ) (7). Depression and other preexisting psychiatric disorders may be exacerbated by HIV (8;9). Depression or other negative impacts on mental health may be a side effect of certain HIV medications (10). Some studies in the post-haart era suggest that certain HIV medications show side effects related to depression. Side effects of HIV medications other than those noted in scientific literature may be noted by patients. No significant research has been carried out on self reported symptoms of HIV versus side effects of medication.

Some HIV antiretroviral medications specifically note depression or strange dreams as a side effect. Please note that while some HIV medications note depression, for all medications it is possible for a patient to experience other side effects. In all cases patients should contact their physician if any unusual problems arise while taking this medication. HIV antiretroviral medications that note depression, strange dreams or night terrors as a possible side effect (11-14): Fusion Inhibitor (FI): o Enfuvirtide Injection Brand name: Fuzeon Other names: T-20; Pentafuside Nucleoside Reverse Transcriptase Inhibitors (NRTIs): o Abacavir Brand name: Ziagen Brand names of combination products: Epzicom (as a combination product containing Abacavir and Lamivudine) Trizivir (as a combination product containing Abacavir, Lamivudine, and Zidovudine) o Emtricitabine Brand names: Emtriva Brand names of combination products: Atripla (as a combination product containing Efavirenz, Emtricitabine, and Tenofovir); Truvada (as a combination product containing Emtricitabine and Tenofovir Disoproxil Fumarate) o Lamivudine Brand names: Epivir, Epivir-HBV Brand names of combination products: Combivir (as a combination product containing Lamivudine and Zidovudine); Epzicom (as a combination product containing Lamivudine and Abacavir Sulfate); Trizivir (as a combination product containing Lamivudine, Abacavir Sulfate, and Zidovudine) Other names: 3TC Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) o Efavirenz (side effect: strange dreams) (15) Brand names: Sustiva Brand names of combination products: Atripla (as a combination product containing Efavirenz, Emtricitabine, and Tenofovir) Protease Inhibitors (PIs)

o Saquinavir Brand names: Invirase, Fortovase o Atazanavir Brand name: Reyataz CCR5 co-receptor antagonists o Maraviroc (side effect: night terrors ) Brand name: Selzentry Key Take Home Messages Depression experienced by people living with HIV or AIDS can be caused by various biological and psychological factors. Eight of the HIV antiretrovirals surveyed list depression as a possible side effect. Some HIV antiretroviral medications have proven serious or lesser side effects related to depression, including strange dreams and night terrors. Factors That May Impact Local Applicability Covering all mental illnesses is beyond the scope of this rapid review response. Our findings are limited to afflictions and side effects described as depression, strange dreams and night terrors. Very few studies have examined depression as a side effect of HAART. Many studies of HIV-related symptoms and treatment side effects do not distinguish individual causal attributions between the two types of problems. The result is a limited ability to differentiate the experience of side effects and disease symptoms on health outcomes such as adherence and quality of life. What We Did We located the literature used in this review by searching Medline using the keywords for highly active antiretroviral therapy, depression, mental health and neurological function 1. In addition, we searched PubMed using text search terms related to HIV anti-retroviral therapy, depression and mental health 2. 1 Medline keywords used: HAART (sub search adverse effects ) AND depression (2); HAART (sub search adverse effects ) AND mental health (1); HAART (sub search adverse effects" AND "Nervous System Physiological Phenomena" (13); HAART NOT "efavirenz" [Substance Name]) AND ("Depression"[Mesh] OR "Depressive Disorder"[Mesh]; "enfuvirtide "[Substance Name] AND "Antiretroviral Therapy, Highly Active/adverse effects"[mesh] 2 PubMed search terms used: nucleoside reverse transcriptase inhibitors AND depression (8); non-nucleoside reverse transcriptase inhibitors AND depression (6); protease inhibitors AND depression (856); HIV AND protease inhibitors AND depression AND adverse effect (10); Fusion Inhibitors AND depression (1);

Reference List (1) Hinkin CH, Castellon SA, Durvasula RS et al. Medication adherence among HIV+ adults: Effects of cognitive dysfunction and regimen complexity. Neurology 2002; 59(12):1944-1950. (2) Judd FK, Mijch AM. Depressive symptoms in patients with HIV infection. Australian and New Zealand Journal of Psychiatry 1996; 30(1):104-109. (3) Bennetts A, Shaffera N, Manopaiboon C et al. Determinants of depression and HIVrelated worry among HIV-positive women who have recently given birth, Bangkok, Thailand. Social Science and Medicine 1999; 49(6):737-749. (4) Gibbie T, Mijch A, Ellen S et al. Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up. HIV Medicine 2006; 7(2):112-121. (5) Hartzell JD, Janke IE, Weintrob AC. Impact of depression on HIV outcomes in the HAART era. J Antimicrob Chemother 2008; 62(2):246-255. (6) Chandra PS, Ravi V, Desai A, Subbakrishna DK. Anxiety and depression among hivinfected heterosexuals a report from india. Journal of Psychosomatic Research 1998; 45(5):401-409. (7) Cohen MA, Hoffman RG, Cromwell C et al. The Prevalence of Distress in Persons With Human Immunodeficiency Virus Infection. Psychosomatics 2002; 43(1):10-15. (8) Ellen SR, Judd FK, Mijch AM, Cockram A. Secondary mania in patients with HIV infection. Australian and New Zealand Journal of Psychiatry 1999; 33(3):353-360. (9) Colibazzi T, Hsu TT, Gilmer WS. Human Immunodeficiency Virus and Depression in Primary Care: A Clinical Review. Primary Care Companion to The Journal of Clinical Psychiatry 2006; 8(4):201-211. (10) Rourke SB, Halman MH, Bassel C. Neurocognitive complaints in HIV-infection and their relationship to depressive symptoms and neuropsychological functioning. Journal of Clinical and Experimental Neuropsychology 1999; 21(6):737-756. (11) American Society of Health-System Pharmacists, National Center for Biotechnology Information (U.S.). AHFS Consumer Medication Information. 2008. Bethesda, MD, The American Society of Health-System Pharmacists, Inc. 23-12-2008. (12) Rafik S, Robert B, Byungse S. Antiretroviral therapy 2006: pharmacology, applications, and special situations. Archives of pharmacal research 2006; 29(6):431-458. (13) WebMD. AIDS and HIV Medication Side Effects. http://www.webmd.com/hiv-aids/aidshiv-medication-side-effects. 2007. 23-12-2008.

(14) Drug Information Online. Prescription drugs: Information, interactions and side effects. http://www.drugs.com/. 10-12-2008. 22-12-2008. (15) Lochet P, Peyrière H, Lotthé A, Mauboussin JM, Delmas B, Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Medicine 2003; 4(1):62-66.